ClinicalTrials.gg
CompletedNCT05812781ExploreUpdated Mar 10, 2025

A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome

A Phase 2 interventional study of VTX2735 and VTX2735 in Cryopyrin Associated Periodic Syndrome, sponsored by Zomagen Biosciences Ltd.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by Zomagen Biosciences Ltd. (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2024, 2 years 8 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Mar 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Cryopyrin-Associated Periodic Syndromes with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Cryopyrin-Associated Periodic Syndromes · United States.

Enrollment
8th of 12
7 · median 21
Started
2023
the only one that year
Phase 2
4 of 15
none open now
Registered
14th of 15
by date
Lead sponsor
1 of 15
Zomagen Biosciences Ltd.

Among the 15 studies in Cryopyrin-Associated Periodic Syndromes with a site in United States, this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2023, is one of 4 in phase 2, and was the 14th registered.

Cryopyrin-Associated Periodic Syndromes

35 studies on the registry are indexed under Cryopyrin-Associated Periodic Syndromes; 5 are open to participants now.

Browse Cryopyrin-Associated Periodic Syndromes studies →

Open to participants now

2 of the 15 studies in Cryopyrin-Associated Periodic Syndromes with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Cryopyrin-Associated Periodic Syndromes studies recruiting now, 1 sets no upper age limit and none stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Cryopyrin-Associated Periodic Syndromes with a site in United States, or all of them as a file.
02

Study summary

This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Cryopyrin-Associated Period Syndrome (CAPS). Approximately 10 patients will take VTX2735 Dose A or VTX2735 Dose B.

The study consists of a screening/washout period of up to 28 weeks, a 2 week treatment period, a treatment withdrawal period of up to 2 weeks, another 2 week treatment period, and a 4 week follow up period. The maximum length of treatment is 4 weeks.

03

Conditions studied

  • Cryopyrin Associated Periodic Syndrome

Keywords

  • Cryopyrin-Associated Periodic Syndrome
  • Ventyx
  • Zomagen
  • VTX2735
  • CAPS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age
  • Diagnosis of CAPS and FCAS subtype and mild clinical phenotype
  • At least one flare during screening/washout
  • Women must not be of or must agree to use two methods of highly effective during the study and for 30 days after the last dose of the study product
  • Men with a partner who is of childbearing potential must agree to use condoms plus another highly effective form of birth control during the study and for 90 days after the last dose of study product

Exclusion criteria

Exclusion Criteria:

  • Unwilling to comply with washout of anti-IL-1 therapy and tolerate symptoms of disease flare
  • Moderate or severe CAPS manifestations or significant damage or any CAPS feature that presents a to washout of anti-IL-1 therapy
  • Has a history of chronic or recurrent infectious disease
  • Has a known immune deficiency or is
  • Has or infection, (HIV), acquired immunodeficiency syndrome (AIDS), or active tuberculosis (TB)
  • Has another medical disorder that would compromise safety
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Drug: VTX2735

  • Experimental
    Cohort 2

    Drug: VTX2735

Interventions

  • DrugVTX2735

    Dose A

  • DrugVTX2735

    Dose B

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of VTX2735

    Incidence and severity of treatment-emergent adverse events (TEAE), serious adverse events (SAE), and discontinuation due to adverse events

    Time frame: From the initial administration of VTX2735 through study completion, up to 10 weeks

Secondary outcomes

  1. Mean change in the mean key symptom score (KSS) derived from the Daily Health Assessment Form, Second Generation (DHAF2) from baseline

    Assess the change from baseline in disease activity using DHAF2 and KSS.

    Time frame: From Day 1 to completion of treatment with VTX2735, up to Day 28

  2. Achievement of 30%, 50%, or 75% improvement in mean KSS from baseline

    Proportion of patients achieving 30%, 50%, or 75% improvement from baseline in disease activity using DHAF2 and KSS.

    Time frame: From Day 1 to completion of treatment with VTX2735, up to Day 28

  3. Number of days when the daily KSS is >3

    Number of multi-system disease flare days as defined by KSS

    Time frame: From Day 1 to completion of treatment with VTX2735, up to Day 28

  4. Number of days when any single DHAF2 symptom score is >3

    Number of single system disease flare days as defined by KSS

    Time frame: From Day 1 to completion of treatment with VTX2735, up to Day 28

  5. Maximum severity of any symptom score on DHAF2

    Maximum single DHAF2 symptom score

    Time frame: From Day 1 to completion of treatment with VTX2735, up to Day 28

07

Study locations

2 sites
  • Local Site # 222
    San Diego, California 92123, United States
  • Local Site # 223
    Columbus, Georgia 31904, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Mar 2024, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2023
First posted
Apr 14, 2023
StartActual
Mar 18, 2023
Primary completionActual
Mar 6, 2024
CompletionActual
Mar 6, 2024
Results delay requested
Mar 5, 2025
Last update
Mar 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05812781
Responsible party
Sponsor
First posted
Apr 14, 2023
Start date
Mar 18, 2023
Primary completion
Mar 6, 2024
Completion
Mar 6, 2024
Last update
Mar 10, 2025

Study contacts

Henrik Sonnergren, MD, PhD
study director · Ventyx Biosciences, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion